Tirzepatide is the only licenced GLP-1/GIP co-agonist for obesity, with several more GLP-1/GIP co-agonists in development [15]
Safety, Adverse Effects, and Regulatory Status Common adverse reactions First, the approved label identifies nausea as the most common adverse reaction
Based on current scientific literature, the areas where MOTS-c shows the most promising effects include: - Improved insulin sensitivity and glucose metabolism: Multiple animal studies have demonstrated improvements in glucose tolerance and insulin sensitivity with MOTS-c treatment - Metabolic health and weight management: By activating AMPK and enhancing fat oxidation, MOTS-c may help achieve/maintain healthier body composition, particularly in the context of diet-induced or age-related metabolic decline - Exercise capacity and endurance: MOTS-c has been shown to improve exercise capacity in animal studies, possibly due to mitochondrial efficiency as well as enhanced muscle metabolism - Healthy aging: MOTS-c is one of the well-studied peptides when it comes to longevity
Have you had any unexplained weight loss
In short: - Glutathione is essential
But clinical trial comparisons across different studies carry significant caveats
